openPR Logo
Press release

Asia Pacific RNA-Based Therapeutics Market Boost in the Emerging economies such as India, China, Singapore and Malaysia due to improving healthcare standards.

02-18-2019 07:31 PM CET | Health & Medicine

Press release from: Allied Market Research

Asia Pacific RNA-Based Therapeutics Market Boost in

The RNA-based therapeutics involves broad range of the RNA-based technologies, which help the patients to diagnose or treat various chronic diseases. The RNA-based therapeutics play a crucial role in providing the accurate and precise healthcare treatments, which helps in treating the disease at molecular and sub-molecular levels.

Get the Sample Report: https://www.alliedmarketresearch.com/request-toc-and-sample/1210?utm_source=openpr&utm_medium=Niranjan

RNA-based therapeutic modalities provide beneficial business opportunities due to its rising acceptance, technological advancements and targeted drug delivery of these therapeutics as compared to the other treatment modalities (synthetic therapeutics). The Asia-Pacific RNA-based therapeutics market is growing at a promising CAGR due to the gene silencing potential of these therapeutics. However, the market is still at the nascent stage in developing regions such as India and witnessing the lucrative growth rate during the analysis period.

Factors that would fuel the market growth in Asia-Pacific region are target specificity and selectivity of RNAi therapeutics, more intense product focus versus platform technologies and virtual drug development models that enable companies to reduce the research cost. However, high cost coupled with the high failure rates and reimbursement issues related with the adoption of RNA-based therapeutics would restrain the market growth.

The Asia-Pacific RNA-based therapeutics market is segmented on the basis of technology, application, end user and geography. Based on technology, the market is segmented into enabling technologies, enabled technologies and RNA antisense technologies. Owing to the applications, the market is segmented into cardiovascular diseases, kidney diseases, oncology infectious diseases and metabolic disorders. Based on the end users, the market is categorized into diagnostic, therapeutic and research organizations.

For Purchase Inquiry: https://www.alliedmarketresearch.com/purchase-enquiry/1210?utm_source=openpr&utm_medium=Niranjan

Geographically, the market is segmented into China, Japan, India, Australia and others. Emerging economies such as India, China, Singapore and Malaysia are the potential geographies for market expansion due to improving healthcare standards. These economies have a large presence of domestic manufacturers of RNA-based therapeutics, which contribute to an increase in the market competition for multinational giants by adopting the strategy of price penetration.

Companies profiled in this report are Genzyme Corporation, Tekmira Pharmaceuticals Corp, Biocon ltd, Nitto Denko Corporation, Alnylam Pharmaceuticals, Inc. Acorda Therapeutics Inc., Arrowhead Research Corporation, Abingworth Life Science, Silence Therapeutics PLC, AstraZeneca Inc., and Catalyst Biosciences.

KEY BENEFITS

This report includes extensive coverage of the Asia-Pacific RNA-based therapeutics market including drivers, restraints and opportunities that would help professionals to better understand market behavior. Analyzing the current market trends, projections regarding the market potential for the period of 20142021 in terms of value are discussed. A comprehensive analysis of device types, end users and geography segments enables the identification of growth opportunities within the Asia-Pacific RNA-based therapeutics market. Market attractiveness analysis for the market would provide strategic assistance to decision makers. An analysis of strategies used by key leaders within the Asia-Pacific RNA-based therapeutics market would prove to be informative for professionals in the corporate sector
Porters five forces framework examines the competitive structure of Asia-Pacific RNA-based therapeutics market and would be helpful for strategic industry analysis. Ease of doing business analysis would help in making strategic business decisions.

ASIA PACIFIC RNA-BASED THERAPEUTICS MARKET KEY SEGMENTS

The Asia-Pacific RNA-based therapeutics market is segmented on the basis of technology, application, end users and geography segments.

BY TECHNOLOGY
• Enabling technologies
• Microarrays
• Labelling
• Purification
• Linear amplification
• QRT-PCR
• Inhibition
• Enabled technologies
• RNA Interference (RNAi) technologies
• Small interfering RNA (siRNA)
• MicroRNA (miRNA)
• RNA antisense technologies

BY APPLICATIONS
• Cardiovascular
• Kidney diseases
• Oncology
• Infectious diseases
• Metabolic disorders
• Others

BY END USERS
• Research
• Therapeutics
• Diagnosis

BY GEOGRAPHY
• China
• Japan
• India
• Australia
• Others

About Us:-

Allied Market Research (AMR) is a full-service market research and business consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of "Market Research Reports" and "Business Intelligence Solutions.” AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.
We are in professional corporate relations with various companies and this helps us in digging out market data that helps us generate accurate research data tables and confirms utmost accuracy in our market forecasting. Each and every data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of domain concerned. Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry.

Contact Us:-

David Correa
5933 NE Win Sivers Drive
#205, Portland, OR 97220
United States
USA/Canada (Toll Free):
+1-800-792-5285, +1-503-894-6022, +1-503-446-1141
UK: +44-845-528-1300
Hong Kong: +852-301-84916
India (Pune): +91-20-66346060
Fax: +1(855)550-5975
help@alliedmarketresearch.com
Web: https://www.alliedmarketresearch.com

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Asia Pacific RNA-Based Therapeutics Market Boost in the Emerging economies such as India, China, Singapore and Malaysia due to improving healthcare standards. here

News-ID: 1597236 • Views: 439

More Releases from Allied Market Research

Brain Health Supplements Market – Know Latest Trends & Forecast for Long-Term …
UPDATE AVAILABLE ON-DEMAND Brain health supplements are balanced blend of herbal extracts and nutrients that are used to improve brain functions such as concentration, focus, and memory. The global brain health supplements market was valued at $3,194 million in 2016, and is expected to reach $5,813 million by 2023, growing at a CAGR of 8.8% from 2017 to 2023. Download Report Sample @ https://www.alliedmarketresearch.com/request-sample/4581 Rise in awareness about brain health supplements, growth in number
Apheresis Market to High trend Opportunities offers Future Business Growth by 20 …
UPDATE AVAILABLE ON-DEMAND According to the report by Allied Market Research, the global Apheresis market is estimated to register a CAGR of 7.3% from 2017 to 2023. The research helps leading players and startups to devise new strategies based on current market trends and changing dynamics. Competitive landscape is mentioned in the report based on business segments, products portfolio, and strategic moves & developments of leading market players. Detailed segmentation assists
Medical Computer Carts Market New Business Opportunities and Investment Research …
UPDATE AVAILABLE ON-DEMAND According to the research report published by Allied Market Research, the global Medical Computer Carts market is expected to register a CAGR of 17.3% from 2017 to 2023. The research includes changing market dynamics, top impacting factors, key investment pockets, value chain, and competitive scenario. Through tabular and graphical representation, the report offers key insights on different aspects of the market such as current market size and estimations,
Medical Simulation Market Huge Demand in COVID-19: Regional Outlook, Trends, Key …
The Medical Simulation market report offers a comprehensive analysis of the study of the industry. The report provides the proper segmentation along with all the CAGR values for the forecast period 2020-2027. A wide range of features including the drivers, restraints, and future opportunities are also provided through the report. The report along with it also involves the analyses of rising trends and upcoming challenges in the market. The marketing

All 5 Releases


More Releases for RNA

RNA Therapy Improves Vision in Child Blindness, hear more about recent developme …
SMi Reports: In light of recent developments in the field of RNA Therapy, SMi’s 10th Annual RNA Therapeutics is set to deliver the latest advancements in February this year. Leber congenital amaurosis (LCA), one of the most common causes of blindness in children, has been the subject of successful RNA therapy as researchers at the University of Pennsylvania recently published new data showing the success of the new therapy which improved
Automated DNA/RNA Isolation System Market Overview Till 2018-2023
Future Market Reports on Global Automated DNA/RNA Isolation System 2018 Research Report presents a professional and complete analysis of on the current Industry situation. The Global report includes Automated DNA/RNA Isolation System Revenue, market Share, industry volume, Trends, Growth aspects. It analyses the important factors of the based on present industry situations, demands, business strategies utilized by Automated DNA/RNA Isolation System market players and the future prospects from various angles
RNA Sequencing: Technologies and Analyses of Global Market Trends
"The Latest Research Report RNA Sequencing: Technologies and Global Markets provides information on pricing, market analysis, shares, forecast, and company profiles for key industry participants. - MarketResearchReports.biz" The global RNA-Sequencing market reached nearly $1.1 billion in 2015, and should reach $1.2 billion in 2016 and $2.1 billion in 2020, registering a compound annual growth rate (CAGR) of 14.9%. The tools and reagents segment should reach over $1.0 billion in 2020 from $566.8
Topics Presented this February 2018 at RNA Therapeutics
SMi’s RNA Therapeutics will be bringing a global presence from MHRA, The RNA Institute, MiNA Therapeutics, AstraZeneca R&D, GSK, Sanofi, CureVac and more. With an agenda full of exciting and new approaches, examine the latest developments in delivery systems for RNA Therapeutics, including Exosomes, Nanocomplexes and Platform Delivery Approaches and patenting RNA Therapeutics. www.therapeutics-rna.com/opr Spotlight: Want to learn about exploiting exosomes for therapeutic use in patients with cystic fibrosis? Have questions answered during
RNA Analysis Market worth 3.62 billion USD by 2021
RNA Analysis Market size was around USD 1.89 billion in 2016. It is expected to grow at a CAGR of 13.9% to reach USD 3.62 billion by 2021. The market is mainly driven by the increasing technological advancements, increasing investment in research and development by biotechnology and pharmaceutical companies, rising government and private funding, and growing preference for personalized medicines. However, lack of skilled professionals in the transcriptomics field and lack
New Confirmed Delegates & Speakers for RNA Therapeutics
SMi are thrilled to welcome Dr. James Hamilton, Vice President, Head of Clinical Development, Arrowhead Pharmaceuticals onto the speaker panel RNA Therapeutics 2018! Dr. James Hamilton is currently responsible for all aspects of clinical trial design, implementation and execution. In this role, Dr. Hamilton managed the ARC-520 and ARC-AAT global programs through Phase 2 of development. Previously, Dr. Hamilton was Medical Director and Head of Corporate Development at Arrowhead. He led